House Call: Botox treatment can relieve chronic migraine headaches
Do you or does someone you know experience 15 or more headaches per month? If so, do these headaches last at least four hours or more, and has it been an ongoing issue for more than six months? If...
View ArticleFDA Issues Complete Response Letter for XARELTO® (rivaroxaban) to Reduce the...
RARITAN, N.J., June 28, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) today announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the...
View ArticleRaptor Pharmaceutical's PROCYSBI(TM) Receives Positive Recommendation From...
(Source: Raptor Pharmaceutical Corp) NOVATO, Calif., June 28, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced today that the European Committee for Medicinal...
View ArticleRaptor Pharmaceutical's PROCYSBI(TM) Receives Positive Recommendation...
NOVATO, Calif., June 28, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced today that the European Committee for Medicinal Products for Human Use (CHMP) has adopted a...
View ArticleFuse Science Technology Provides Superior Roll-On Alternative for $1.7...
MIAMI LAKES, Fla., June 27, 2013 /PRNewswire/ -- Fuse Science, Inc. (OTCQB: DROP) (www.fusescience.com), a consumer products and delivery technology company that is developing new, patent-pending...
View ArticleRegulatory Update - GSK receives positive CHMP opinions for Tafinlar®...
(Source: GSK - GlaxoSmithKline plc) Issued: Friday 28 June 2013, London UK Today, GlaxoSmithKline plc (GSK) announced that the European Medicines Agency's Committee for Medicinal Products for Human...
View ArticleZogenix and Valeant Pharmaceuticals Enter Exclusive Co-Promotion Agreement...
SAN DIEGO, June 27, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain,...
View ArticleSucampo Receives $10 Million Milestone Payment from Takeda on First Sale of...
(Source: Sucampo Pharmaceuticals Inc) Sucampo Receives $10 Million Milestone Payment from Takeda on First Sale of AMITIZA® (lubiprostone) for OIC in the US AMITIZA is the World's First and Only Oral...
View ArticleSucampo Receives $10 Million Milestone Payment from Takeda on First Sale of...
AMITIZA is the World’s First and Only Oral Medication Approved for Treatment of Opioid-Induced Constipation in Adults with Chronic, Non-cancer Pain BETHESDA, Md.--(BUSINESS WIRE)--Sucampo...
View ArticleKroll Bond Rating Agency Assigns BBB+ Rating to Prospect Capital Corporation
Tweet Send to a Friend NEW YORK--(BUSINESS WIRE)-- Kroll Bond Rating Agency (KBRA) announces the assignment of a BBB+ rating with a stable outlook to Prospect Capital Corporation, a Business...
View ArticleHormone therapy in the 50s not linked to memory loss
NEW YORK (Reuters Health) - Hormone replacement therapy during the early stages of menopause - typically around age 50 - doesn't hurt or help brain function, according to a new study. Researchers...
View ArticleNovartis Exelon® Patch now FDA approved to treat patients across all stages...
- Latest FDA approval based on high dose Exelon Patch 13.3 mg/24h for severe Alzheimer's; 24-week study showed statistically significant improvement in overall cognition and function compared to 4.6...
View ArticleHormone therapy, calcium may lower fracture risk
NEW YORK (Reuters Health) - Women taking a combination of hormone therapy and calcium and vitamin D tablets after menopause were less likely to fracture their hip than those not taking hormones or...
View ArticleFinding a balance with hormone replacement therapy
After a decade of rancorous debate over the risks and benefits of menopausal hormone therapy, experts from more than a dozen top medical organizations worldwide have finally come to something...
View ArticleFDA approves first non-hormonal treatment for menopausal hot flashes
June 28 (Reuters) - The U.S. Food and Drug Administration approved Noven Therapeutics LLC's drug to treat hot flashes associated with menopause - a surprise decision as an advisory committee to the...
View ArticleHisamitsu Wins U.S. Approval for Drug to Ease Hot Flashes
Hisamitsu Pharmaceutical Co. (4530)’s Noven unit won U.S. approval for its drug to ease hot flashes associated with menopause. The Food and Drug Administration said today it cleared the drug, to be...
View ArticleFDA approves an antidepressant for hot flashes
Is it hot in here, or am I just depressed? For many menopausal women, hot flashes are just depressing. And depression, which affects at least one in four women ages 40 to 59, can intensify the misery...
View ArticleNoven Receives FDA Approval for Brisdelle™ (Paroxetine) Capsules, the First...
Brisdelle™ is the first and only FDA-approved nonhormonal therapy clinically proven to treat moderate to severe menopausal vasomotor symptoms Tweet Send to a Friend MIAMI, FL and NEW YORK, NY, June...
View ArticleManaging Menopause Your Way (Northwestern University)
(Source: Northwestern University) CHICAGO --- Should you take hormone therapy during menopause? What's the latest research about its safety? And what are non-hormone alternatives for managing hot...
View ArticleMenopausal hormone therapy a relief for some women
Julie Deardorff Chicago Tribune Comments After a decade of rancorous debate over the risks and benefits of menopausal hormone therapy, experts from more than a dozen top medical organizations...
View Article